Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma

Annals of Oncology

Volumn 7, Issue 10, 1996, Pages 1043-1049

  Prince, H M ^a   Crump, M ^a,b   Imrie, K ^a   Stewart, A K ^a   Girouard, C ^a   Brandwein, J M ^a   Carstairs, K ^a   Pantalony, D ^a   Scott, G ^a   Sutcliffe, S ^a   Sutton, D M C ^a   Tsang, R ^a   Keating, A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Hodgkin's disease; induction failure; non Hodgkin's lymphoma; refractory lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ETOPOSIDE; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 12644266363     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010497     Document Type: Article

References (43)

1. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
2. DeVita VT, Molloy Hubbard S. Hodgkin's disease. N Engl J Med 1993; 328: 560-5.
3. Colwill R, Crump M, Couture F et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995; 13: 396-402.
4. Bonadonna G, Viviani S, Valagussa P et al. Third-line salvage chemotherapy in Hodgkin's disease. Semin Oncol 1985; XII: 23-5.
5. Chopra R, Linch DC, McMillan AK et al. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 1992; 81: 197-202.
6. Santoro A, Viviani S. Valagussa P et al. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 1986; 13: 23-6.
7. Pfreundschuh MG, Schoppe WD, Fuchs R et al. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, and dacarbazine (ABVD): A multicenter trial of the German Hodgkin Study Group. Cancer Treat Rep 1987; 71: 1203-7.
8. Hagemeister FB, Tannir N, McLaughlin P et al. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 1987; 5: 556-61.
9. Perren TJ, Selby PJ, Milan S et al. Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease. Br J Cancer 1990; 61: 919-23.
10. Smith MR, Khanuja PS, Al-Katib A et al. Continuous infusion ABDIC therapy for relapsed or refractory Hodgkin's disease. Cancer 1993; 73: 1264-9.
11. Pfreundschuh MG, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580-6.
12. Tseng AJ, Jacobs C, Coleman CN et al. Third line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. Cancer Treat Rep 1987; 71: 475-8.
13. Tourani J, Levy R, Colonna P et al. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol 1992; 10: 1086-94.
14. Brusamolino E, Orlandi E, Canevari A et al. Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease. Ann Oncol 1994; 5: 427-32.
15. Roach III M, Kapp D, Rosenberg SA et al. Radiotherapy with curative intent: An option in selective patients relapsing after chemotherapy for advanced Hodgkin's disease. J Clin Oncol 1987; 5: 550-5.
16. Fox KA, Lippman SM, Cassady JR et al. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. J Clin Oncol 1987; 5: 38-45.
17. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-94.
18. Cabanillas F, Hagemeister FB, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refactory lymphoma. J Clin Oncol 1987; 5: 407-12.
19. Velasquez WS, Cabanillas F, Salvador P et al. Effective salavage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone [DHAP]. Blood 1988; 71: 117-22.
20. Cabanillas F, Hagemeister FB, Bodey GP et al. IVMP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693-7.
21. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP: An effective chemotherapy regimen in refactory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 1994; 12: 1169-76.
22. Stewart AK, Brandwein JM, Sutcliffe SB et al. Mini-BEAM as salvage chemotherapy for refactory Hodgkin's disease and non-hodgkin's lymphoma. Leuk Lymph 1991; 5: 111-5.
23. Wilson WH, Bryant G, Bates S et al. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-82.
24. Chao NJ, Rosenberg SA, Horning SJ. CEPP [B]: An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 1990; 76: 1293-8.
25. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-4.
26. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin lymphoma. N Engl J Med 1995; 333: 1540-5.
27. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 1993; 11: 704-11.
28. Prince HM, Keating A. Autologous bone marrow and blood cell transplantation with etoposide and melphalan for poor prognosis non-Hodgkin's lymphoma: The importance of disease status at transplant. In Dicke KA, Keating A (eds): Autologous Marrow and Blood Transplantation. Proceedings of the Seventh International Symposium. Arlington, TX: The Cancer Treatment Research and Educational Institute 1995; 339-55.
29. Girouard C, Dufresne J, Imrie K et al. Salvage chemotherapy with Mini-BEAM for relapsed or refractory non-Hodgkin lymphoma prior to autologous bone marrow transplant. Submitted 1996.
30. Brandwein J, Callum J, Rubinger M. An evaluation of out-patient bone marrow harvesting. J Clin Oncol 1989; 7: 648-50.
31. Martin-Algarra S, Bierman PJ, Anderson J et al. Cyclophosphamide, BCNU, and VP-16 followed by autologous bone marrow or peripheral blood stem cell transplantation in Hodgkin's disease [HD]. Retrospective analysis of 10 years experience at the University of Nebraska Medical Center [UNMC]. Blood 1994; 84 (Suppl 1 ): 536a (Abstr 2131).
32. Bierman PJ, Vose JM, Armitage JO. Autologous transplantation for Hodgkin's disease: Coming of age? Blood 1994; 83: 1161-4.
33. Hurd DD, Haake RJ, Lasky LC et al. Treatment of refractory and relapsed Hodgkin's disease: Intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support. Med Pediatr Oncol 1990; 18: 447-53.
34. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137-45.
35. Yahalom J, Gulati SC, Toia M et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11: 1062-70.
36. Carrella AM, Congiu AM, Gaozza E et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian Study Group report. J Clin Oncol 1988; 6: 1411-6.
37. Reece DE, Barnett MJ, Shepherd JD et al. High-dose cyclophosphamide, carmustine [BCNU], and etoposide [VP16-213] with or without cisplatin [CBV+P] and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451-6.
38. Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 1994; 12: 2543-51.
39. Gianni AM, Bregni M, Siena S et al. 5-Year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs. MACOP-B therapy for diffuse large-cell lymphomas. Proc Am Soc Clin Oncol 1994; 13: 373 (Abstr 1263).
40. Verdonck LF, van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045-92.
41. Goldstone AH, McMillan AK. The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease. Ann Oncol 1993; 4 (Suppl 1): 21-7.
42. Gianni AM, Siena S, Bregni M et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991; 2: 645-53.
43. Darrington DL, Vose JM. Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphiod malignancies. J Clin Oncol 1994; 12: 2527-34.